Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.

  title={Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.},
  author={Yaron Rotman and Arun J Sanyal},
  volume={66 1},
Given the high prevalence and rising incidence of non-alcoholic fatty liver disease (NAFLD), the absence of approved therapies is striking. Although the mainstay of treatment of NAFLD is weight loss, it is hard to maintain, prompting the need for pharmacotherapy as well. A greater understanding of disease pathogenesis in recent years was followed by development of new classes of medications, as well as potential repurposing of currently available agents. NAFLD therapies target four main… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 10 times over the past 90 days. VIEW TWEETS
47 Citations
139 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 47 extracted citations


Publications referenced by this paper.
Showing 1-10 of 139 references

Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor—a randomized Rotman Y

  • ML Shiffman, P Pockros, JG McHutchison
  • Sanyal AJ. Gut 2017;66:180–190
  • 2016

Reduction of liver steatosis and fibrosis with an Ask1 inhibitor in a murine model of nash is accompanied by improvements in cholesterol, bile acid and lipid metabolism

  • G Budas, S Karnik, T Jonnson
  • J Hepatol 2016;64:S170
  • 2016

Sitagliptin versus placebo in the treatment of non-alcoholic fatty liver disease: a randomized controlled trial

  • JY Cui, L Philo, P Nguyen
  • J Hepatol
  • 2016

Similar Papers

Loading similar papers…